A Phase 1 Study of a Tablet Form of ABBV-722 Taken With and Without Food in Healthy Adult Participants

Maximum Observed Plasma Concentration (Cmax) of ABBV-722

Maximum observed plasma concentration (Cmax) of ABBV-722

Time frame: Up to Day 8 of each period (Period 1 is 9 days and Periods 2 and 3 are 8 days each; 3 periods total)

Time to Cmax (Tmax) of ABBV-722

Time to Cmax (Tmax) of ABBV-722

Time frame: Up to Day 8 of each period (Period 1 is 9 days and Periods 2 and 3 are 8 days each; 3 periods total)

Terminal Phase Elimination Rate Constant (β) of ABBV-722

Terminal phase elimination rate constant of ABBV-722

Time frame: Up to Day 8 of each period (Period 1 is 9 days and Periods 2 and 3 are 8 days each; 3 periods total)

Terminal Phase Elimination Half-Life (t1/2) of ABBV-722

Terminal phase elimination half-life of ABBV-722

Time frame: Up to Day 8 of each period (Period 1 is 9 days and Periods 2 and 3 are 8 days each; 3 periods total)

Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUCt) of ABBV-722

Area under the plasma concentration-time curve from time 0 to the time of last measurable concentration (AUCt) of ABBV-722

Time frame: Up to Day 8 of each period (Period 1 is 9 days and Periods 2 and 3 are 8 days each; 3 periods total)

Area Under the Plasma Concentration-Time Curve From Time 0 to Infinite Time (AUCinf) of ABBV-722

Area under the plasma concentration-time curve from time 0 to infinite time (AUCinf) of ABBV-722

Time frame: Up to Day 8 of each period (Period 1 is 9 days and Periods 2 and 3 are 8 days each; 3 periods total)

Number of Participants with Adverse Events (AEs)